tiprankstipranks
Trending News
More News >

OncoSil Medical Reports Record Growth and Strategic Advancements in Q3 FY25

Story Highlights
  • OncoSil Medical achieved record dose sales in Q3 FY25, with a 233% increase.
  • Strategic advancements include new board appointments and advisory meetings in the UK and Germany.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
OncoSil Medical Reports Record Growth and Strategic Advancements in Q3 FY25

Confident Investing Starts Here:

OncoSil Medical Ltd ( (AU:OSL) ) has provided an update.

OncoSil Medical Ltd reported record quarterly dose sales in Q3 FY25, reflecting a 233% increase compared to the previous year, driven by the growing clinical adoption of the OncoSil™ device. The company also received a $1.05 million R&D tax incentive and made strategic appointments and advancements, including the addition of Ms. Lel Smits to the Board of Directors and Ms. Shelley Steyn as CFO. Advisory Board meetings in the UK and Germany outlined strategic pathways for the device’s advancement, aiming to strengthen OncoSil’s position in the healthcare systems of these regions.

More about OncoSil Medical Ltd

OncoSil Medical Ltd is a medical device company specializing in localized treatments for patients with unresectable locally advanced pancreatic cancer. The company focuses on the OncoSil™ device, which is designed to deliver targeted radiotherapy for pancreatic cancer, with a market focus on expanding its clinical adoption and strategic positioning in key geographic areas such as the UK and Germany.

Technical Sentiment Signal: Buy

Current Market Cap: A$18.43M

For an in-depth examination of OSL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1